Phathom Pharmaceuticals, Inc.
NASDAQ:PHATBiotechnology
-$0.27 today
- Market cap
- $412.96M
- Beta
- 0.51
- P/E (TTM)
- -5.6
- EPS (TTM)
- -$1.92
Volume 1.03M
Average 1.21M
Income Statement
Follow revenue through to earnings.
Revenue
$175.11M
FY 2025 · Annual
+216.9% YoYOperating Income
-$159.99M
FY 2025 · Annual
Net Income
-$221.25M
FY 2025 · Annual
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 682K | 55.25M | 175.11M |
| Cost of Revenue | 521K | 620K | 167K | 7.97M | 22.6M |
| Gross Profit | (521K) | (620K) | 515K | 47.28M | 152.51M |
| Gross Margin | — | — | 75.5% | 85.6% | 87.1% |
| Research & Development | 72.34M | 71.44M | 49.9M | 34.08M | 32.78M |
| Selling, General & Admin | 62.22M | 100.38M | 117.93M | 290.66M | 279.72M |
| Operating Expenses | 134.56M | 171.82M | 167.83M | 324.75M | 312.5M |
| Depreciation & Amortization | 521K | 620K | 575K | 795K | 633K |
| EBITDA | (136.57M) | (169.8M) | (159.05M) | (261.52M) | (152.5M) |
| EBITDA Margin | — | — | -23321.0% | -473.3% | -87.1% |
| Operating Income | (135.08M) | (172.44M) | (167.31M) | (277.47M) | (159.99M) |
| Operating Margin | — | — | -24532.6% | -502.2% | -91.4% |
| Interest Income | 41K | 2.13M | 7.88M | 15.16M | 7.04M |
| Interest Expense | 6.79M | 27.31M | 41.97M | 72.01M | 68.12M |
| Other Income / Expenses | (8.8M) | (25.28M) | (34.28M) | (56.86M) | (61.26M) |
| Income Before Tax | (143.88M) | (197.72M) | (201.59M) | (334.33M) | (221.25M) |
| Pre-Tax Margin | — | — | -29558.9% | -605.1% | -126.3% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (143.88M) | (197.72M) | (201.59M) | (334.33M) | (221.25M) |
| Net Margin | — | — | -29558.9% | -605.1% | -126.3% |
| EPS (Basic) | (4.00) | (5.70) | (3.93) | (5.29) | (3.03) |
| EPS (Diluted) | (4.00) | (5.70) | (3.93) | (5.29) | (3.03) |
| 37M | 39.12M | 51.29M | 63.18M | 72.92M | |
| 37M | 39.12M | 51.29M | 63.18M | 72.92M |
PHAT Earnings Waterfall · TTM
NASDAQ:PHAT · Revenue to Net Income
Key Ratios
Analysis
$204.9M of revenue converted into -$157.3M of net income for the selected period. Gross margin is 85.2% and net margin is -85.3%, showing how much revenue survives after costs and taxes. EPS is $-2.12, tying the income statement back to per-share earnings.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| SC 13G/A | SC 13G/A filing | Nov 10, 2026 | |
| SC 13D/A | SC 13D/A filing | Nov 2, 2026 | |
| 10-Q | Quarterly report | Oct 29, 2026 | |
| 8-K | Current report | Oct 29, 2026 | |
| 8-K | Current report | Oct 26, 2026 |
How much revenue does PHAT generate?
Phathom Pharmaceuticals, Inc. (PHAT) reported $175.11M of revenue in fiscal 2025.
Is PHAT profitable?
Phathom Pharmaceuticals, Inc. (PHAT) reported -$221.25M of net income, with a net margin of -126.3%.
Continue the stock analysis
Jump to another research area for this company.